Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Aug 20, 2023 4:33pm
477 Views
Post# 35597089

New week, new posting chain.

New week, new posting chain.

Hi all
Again glad to see the reasonable fair & open back- forth dialog.
My one comment. First I have not read the details of the SEDAR report. Which they published as background of the recent share deal.
The exact details? I understand the 550/ vs 400 patients has come up?
I believe the wording was suggested.
The acrtual,number is what matters. The addition of 150 people & timelines?
depends on number of clinics, locations & overall enrolment.
Quite frankly the timing will be " estimated" once phase  3 is registered with FDA

regardless of looking through the tall grass to find details, I'm more of a big picture person.
The details are the job of the trial investigators, pharma partners & FDA.

Now big picture.
first to clarify, one recent rant going around.
being that mangement shorted the stock to get their cheap options.
That statement is beyond silly. 
understand all of mangement trades must be reported. They simply would not do that.
next, the options have a " strike price". Meaning if/ when they price gets above that, they can buy the shares. Their " option"...
The options are free, but worthless until the price is above the strike price.To gain the value they need to still buy the shares.
many times options just expire.
So it is certainly in managements best interest to see the price above the listed number.

Most importantly, it should be understood. Onc is still working towards a pharma partner for phase 3.
either MBc , panc or both.
When thst i# established & only then we we see exceptional sustainable share price.
im talking above the existing estimates of $3 to $15ps.
None of which include either partner or buyout.
The RBC report for example has a $6 CDN rating, with an $18 upside, if/ when a partner is announced.
When will that be?
we were told parameters of the PanCan trial will be finalized " within 90 days"
That was June 22. So assuming a rough 90 days .
Being Sept 22.
They recently updated the web site presentation.
Have a look.
Lots to see.
meanwhile , I'll dig into 5he SEDAR report.


 

<< Previous
Bullboard Posts
Next >>